Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3SBio Climbs 5% in First Trading Day In Hong Kong

publication date: Jun 11, 2015
3SBio, a Shenyang biotech, rose 5% in its first day of trading in Hong Kong following the company's $711 million IPO. Even though the IPO was priced at 43 times earnings, the IPO had no trouble attracting investors at the top of its range, and then moving higher in open market trading. CITIC Private Equity, which backed the company's privatization, pocketed $177 million of the proceeds, but the remaining $534 million will go to 3SBio, which promised to spend almost half of its new capital to add new products to its already extensive portfolio of development-stage products. More details....

Stock Symbol: (HK: 1530)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital